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473Percutaneous Interventions for
Left Atrial Appendage Exclusion
Options, Assessment, and Imaging Using
2D and 3D EchocardiographyABSTRACTPercutaneous left atrial appendage (LAA) exclusion is an evolving treatment to prevent embolic events in patients with
nonvalvular atrial ﬁbrillation. In the past few years multiple percutaneous devices have been developed to exclude the
LAA from the body of the left atrium and thus from the systemic circulation. Two- and 3-dimensional transesophageal
echocardiography (TEE) is used to assess the LAA anatomy and its suitability for percutaneous closure to select the type
and size of the closure device and to guide the device implantation procedure in conjunction with ﬂuoroscopy. In
addition, 2- and 3-dimensional TEE is also used to assess the effectiveness of device implantation acutely and on
subsequent follow-up examination. Knowledge of the implantation options that are currently available along with their
speciﬁc characteristics is essential for choosing the appropriate device for a given patient with a speciﬁc LAA anatomy.
We present the currently available LAA exclusion devices and the echocardiographic imaging approaches for evaluation
of the LAA before, during, and after LAA occlusion. (J Am Coll Cardiol Img 2015;8:472–88) © 2015 by the American
College of Cardiology Foundation.T he left atrial appendage (LAA) is a tubular,blind-ended pouch attached to the mainbody of the left atrium (LA). It is the source
of cerebral thromboembolism in approximately 90%
of patients with nonvalvular atrial ﬁbrillation (AF)
(1,2).
LAA occlusion or exclusion to prevent embolism
in patients with nonvalvular AF by implanting a
percutaneously delivered device to exclude the LAA
cavity from the systemic circulation has evolved
since the ﬁrst implantation of an LAA occlusion
device in 2001 (3). Currently there are 3 devices
(Figure 1) available for percutaneous implantation
within the LAA and one suture-based technology to
occlude the LAA (Figure 2). European guidelines for
management of AF now recommend that percuta-
neous LAA closure may be considered in high stroke
risk patients with contraindications for long-term
oral anticoagulation (class IIb indication, level of
evidence B) (4).
Transesophageal echocardiography (TEE) is the
main imaging modality used to assess LAA anat-
omy, aid in the selection of a suitable device and size,
and identify anatomic contraindications. Two-
dimensional (2D) and 3-dimensional (3D) TEE are
used in conjunction with ﬂuoroscopy to guide
the procedure, evaluate results after device place-
ment, and monitor for complications. In this review,
we focus on current echocardiographic imaging a-
pproaches for the evaluation of the LAA before,during, and after LAA occlusion, and on the different
imaging aspects in regard to the currently available
devices.
CURRENT DEVICES FOR PERCUTANEOUS
LAA OCCLUSION OR EXCLUSION
As shown in the Central Illustration, as well as in
Figures 1 and 2, knowledge of the different devices
and their characteristics is important for optimal pa-
tient selection and successful guidance of an LAA
closure procedure. All LAA closure devices described
in this review are available for clinical use in Europe.
In the United States, the endoluminally implanted
devices can only be used as part of a clinical trial.
The LAA occluder device (Watchman device, Boston
Scientiﬁc, Natick, Massachusetts) received FDA
approval very recently in March 2015. The LAA
ligation device (LARIAT suture device, SentreHEART,
Inc., Redwood City, California) is approved by the
Food and Drug Administration for suture placement
and knot tying in surgical applications; however, it is
not approved speciﬁcally for treatment of stroke
prevention in patients with AF.
ENDOLUMINAL LAA CLOSURE DEVICES. LAA occluder
device. The LAA occluder device (Figure 1A) is a self-
expanding system with a nitinol frame covered with
a permeable 160 mm polyethylene terephthalate fabric
on the LA side of the device. Ten active ﬁxation
hooks are placed around the circumference. There are
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474more data on outcomes available on the LAA
occluder device than on any other LAA
occlusion system. Randomized studies with
the LAA occluder device (PROTECT-AF
[WATCHMAN Left Atrial Appendage System
for Embolic PROTECTion in Patients With
Atrial Fibrillation] trial; n ¼ 707; 463 device/
244 control) conﬁrmed noninferiority for
LAA occlusion compared with oral warfarin
therapy with regard to the primary compos-
ite endpoint of stroke, cardiovascular or un-
explained death, and all-cause death (5–7).
After 3.8 years of follow-up among
PROTECT-AF patients, percutaneous LAA
closure met criteria for both noninferiority
and superiority, compared with warfarin, forpreventing the combined outcome of stroke, sys-
temic embolism, and cardiovascular death, as well
as superiority for cardiovascular and all-cause mor-
tality (8).
In the randomized PREVAIL (Evaluation of the
Watchman LAA Closure Device in Patients With AtrialE 1 Endoluminal LAA Occlusion Devices
nt endoluminal LAA occlusion devices (far left column). (A) LAA
ion device (device images with permission from Boston Scientiﬁc,
ferent devices using different imaging modalities after device pla
y 2D TEE [middle column] and 3D TEE [right column]). 2D ¼ 2-
transesophageal echocardiography.Fibrillation Versus Long Term Warfarin Therapy) trial
(n ¼ 407; 269 device/138 control), a continuum of the
PROTECT-AF trial, LAA occlusion was noninferior to
warfarin for ischemic stroke prevention or systemic
embolism >7 days post-procedure. Although non-
inferiority was not achieved for overall efﬁcacy, event
rates were low and numerically comparable in both
treatment arms (device implantation vs. chronic
warfarin therapy) (9). Registry data on 610 patients
have also been published (10–12).
First Generation LAA Plug. The ﬁrst generation LAA
plug (Amplatzer Cardiac Plug, St. Jude Medical, Inc.,
St. Paul, Minnesota) (Figure 1B) device is designed to
occlude the full cross-sectional area of the LAA
oriﬁce. The device is made of a ﬂexible braided nitinol
mesh and has 2 major components: a distal lobe with
6 pairs of hooks attached and a proximal disc to cover
the ostium. A central waist constitutes an articulat-
ing, compliant connection between the disc and the
lobe. Nonrandomized trials with the ﬁrst generation
LAA plug demonstrate feasibility, effectiveness in
reducing thromboembolic cerebral events, and a highoccluder device. (B) First generation LAA plug. (C) Flexible LAA
St. Jude Medical, Inc., and Coherex Medical, Inc.). The appearance of
cement is shown (ﬂuoroscopy [left column] followed by echocardi-
dimensional; 3D ¼ 3-dimensional; LAA ¼ left atrial appendage;
FIGURE 2 LAA Ligation Device and Different Imaging Modalities Pre- and Post-Procedure
(A) Computed tomography imaging of favorable LAA anatomy is shown in a lateral view with the LAA in the foreground. The LAA is lateral to
the PA (with permission from SentreHEART, Inc.). The major component of the system consists of a collapsible snare with a pre-tied suture loop
(1). (B) Via transseptal access, a magnetic wire is placed inside the LAA (2). A second magnetic wire is introduced via a percutaneous epicardial
approach and directed toward the magnetic wire in the LAA (3). Once both magnets are engaged, a magnetic wire bridge is created (2, 3). Using
this endocardial/epicardial magnetic wire bridge as guide rail an endocardial compliant balloon is delivered, which is inﬂated at the LAA ostium
to mark the “landing zone” for the suture (4). Coming from the epicardial side the LAA ligation device suture-loop is inserted over the wire,
placed around the LAA, and snared close to the LAA ostium above the inﬂated balloon (1). The suture is tightened by using a pre-tied one-way
slip knot, ultimately resulting in LAA closure. (C) Fluoroscopic image of the suture-loop placed around the LAA above the inﬂated balloon. (D) A
2D TEE image with color Doppler demonstrating no residual ﬂow within the LAA cavity. The white arrowhead points at the location of the
suture close to the LAA ostium. (E) A 3D TEE enface image of the LAA ostium after successful LAA closure with the LAA ligation device.
The black arrowhead points at the LAA ostium. Ao ¼ aorta; LA ¼ left atrium; LV ¼ left ventricle; PA ¼ pulmonary artery; other abbreviations
as in Figure 1.
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475rate of technical success (13–16). Data on nearly 2,000
ﬁrst generation LAA plug patients are published. Most
of them were implanted in Europe, 20 in Asia, and
52 in Canada (10,13–17). A second-generation LAA plug
(AMPLATZER Amulet LAA occluder, St. Jude Medical,
St. Paul, Minnesota) is also being tested in clinical
trials (18). The second generation LAA plug allows for
larger LAAs to be treated. This device design has a
slightly larger disc than the ﬁrst generation LAA plug
to better occlude the LAA ostium. The waist and the
lobe are longer compared with the ﬁrst generation
LAA plug and the number of stabilizing wires sur-
rounding the device body is increased for improved
device ﬂexibility and stability.
Flexible LAA occlusion device. The ﬂexible LAA occlu-
sion device (Coherex WaveCrest, Coherex Medical,Inc., Salt Lake City, Utah) (Figure 1C) was approved for
use in Europe in September 2013. This umbrella-
shaped device consists of a nitinol frame with 20
anchoring points. An occlusive, nonthrombogenic
expanded polytetraﬂuoroethylene membrane covers
the LA side of the device. A polymer foam around the
device faces the LAA side. Preliminary clinical expe-
rience with the ﬂexible LAA occlusion device (n ¼ 63)
demonstrated high closure rates of 97% and a good
safety proﬁle (19).
EPICARDIAL APPROACH FOR LAA LIGATION.
Figure 2 shows the LAA ligation device. This device is
designed to occlude the LAA percutaneously using a
suture. The percutaneous catheter-based LAA liga-
tion using the LAA ligation device has been shown to
TABLE 1 LAA Region
LAA Region
The ostium Ope
t
i
The neck The
r
a
t
l
The lobar region Larg
d
LA ¼ left atrium; LAA ¼ le
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476be feasible and effective in humans and complete
closure of the LAA has been achieved in observational
studies and 1 retrospective multicenter study in the
United States (n ¼ 277 with successful device im-
plantation) (20–23).
IMAGING MODALITIES AND
GENERAL IMAGING ASPECTS IN
PROCEDURE PLANNING
As described in Table 1 and shown in Figure 3, it is
useful to divide the LAA anatomically into 3 regions:
1) the ostium; 2) the neck; and 3) the lobar region.
There is broad variability in LAA morphology, a fact
that complicates adequate evaluation (24). LAA
ostium diameters range from 10 to 40 mm, its length
from 16 to 51 mm, with volumes from 0.7 to 19.2 ml.
On postmortem evaluation it was demonstrated that
LAA from patients with AF have 3 times the volume
of those who were in sinus rhythm (25). Patients
with chronic AF frequently have LAA remodeling in
which there is dilation, stretching, and reduction in
pectinate muscle volume, as well as endocardial
ﬁbroelastosis (25).s, Their Anatomic Characteristics, Neighboring Structures, and Speciﬁc C
Anatomic Description Anatomic Characteristics Ne
ning from the LA
o the LAA (the ostium
s usually a well-deﬁned plane)
Generally oval in shape (26,27)
The wall around the ostium
can be very thin (27)
MV (27)
Left uppe
ostium opens to a neck
egion that constitutes
tubular junction between
he ostium and the
obar region
Pits or troughs and areas of
thin atrial wall were found
in w58% of hearts within a
w21-mm radius from the
ostium (27)
Secondary lobes may originate
close to the ostium
Circumﬂex
Left anter
Sinus nod
est and most variable
istal part of the LAA
1–5 lobes may be present (26,27)
Small crevices and areas of very
thin wall were found (27)
The tip of
the ba
the lef
anterio
cardia
The left p
the pe
the LA
ft atrial appendage; MV ¼ mitral valve.Important aspects for LAA occlusion include the
correct sizing of the landing zone diameters for the
selected device and the measurement of the depth
and orientation of the main anchoring lobe and the
number and origin of additional lobes. In >50% of
patients, 2 or more lobes are present (26,27).
Because of the substantial variations in LAA anat-
omy that impact device selection and efﬁcacy, as
detailed in Table 1, an accurate assessment of
anatomic LAA characteristics is crucial before an LAA
closure procedure. LAA imaging modalities used
include transthoracic echocardiography (TTE), TEE,
multidetector computed tomography (MDCT), and
cardiac magnetic resonance (CMR).
TTE. Before an LAA closure procedure, 2D and 3D
TTE is used to evaluate LA dimensions and volumes
(28,29) and left ventricular function (a risk factor
for thromboembolism [30]), and to exclude contra-
indications for LAA closure (e.g., patients with
valvular AF) or signiﬁcant valve disease requiring
surgery or patients with a left ventricular thrombus
or a mechanical heart valve who require chronic
anticoagulation.onsiderations With Regard to Percutaneous LAA Closure
ighboring Structures
Speciﬁc Considerations
With Regard to
LAA Closure
r pulmonary vein (27)
A very eccentric LAA ostium may be
problematic for device placement
(risk of peridevice leakage)
Thin wall areas increase the risk
of perforation
The MV or the left upper pulmonary vein
may be altered by a device
coronary artery (27)
ior descending artery (27)
e artery (in w30%) (27)
A severe angulation between the ostium
and the neck may cause technical
problems
Areas of thin wall increase the risk of
perforation
A lobe that originates very close to the
ostium may stay unsealed
Coronary arteries can be at risk during
LAA occlusion
the appendage overlaps
se of the pulmonary trunk,
t coronary artery, or its
r branch and the great
c vein at varying levels (27)
hrenic nerve runs along
ricardium overlaying
A (27)
The main anchoring lobe needs to be long
enough to accommodate the selected
device
An LAA, which is located underneath a
pulmonary artery, is not suitable for
a suture approach
Pericardial access may potentially cause
damage to the left phrenic nerve
Areas of thin wall increase the risk of
perforation
Coronary arteries can be at risk during
LAA occlusion
Speciﬁc morphologies (e.g., a chicken
wing morphology) may need speciﬁc
implantation strategies for LAA closure
FIGURE 3 Echo-Anatomy of the LAA
The LAA regions are illustrated in a 2D TEE view (45) (A) and in a corresponding anatomic image (B). The black arrowhead in (A)marks the Lcx.
Relationship between the LAA, the LUPV, and the MV are shown in a 3D TEE aspect (C) and in an anatomic picture (D). Lcx ¼ left circumﬂex
coronary artery; LUPV ¼ left upper pulmonary vein; MV ¼ mitral valve; other abbreviations as in Figure 1.
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477TEE. Pre-procedure TEE is the main imaging modality
because the LAA cannot be deﬁnitively assessed by
TTE. The close relationship of the esophagus and the
LA allows detailed imaging of the LAA in most pa-
tients (31). Among other things TEE is used to exclude
thrombi in the LA and LAA (32). 3D TEE is helpful in
differentiating a thrombus from LAA pectinate mus-
cles (33). In case there is uncertainty about the pres-
ence of a clot, the use of ultrasound contrast is helpful
to identify these thrombi (34). Pre-procedure TEE is
also used to exclude other sources of embolism, such
as cardiac masses and thrombi (3D TEE has shown to
be more accurate compared with 2D TEE in charac-
terizing diameters, types, surface features, mobility,
and sites of intracardiac masses, and spatial relation-
ship to surrounding structures [35–38]) as well as
aortic arch atheroma. If an LA/LAA thrombus is diag-
nosed, anticoagulant therapy should be given until
the thrombus has resolved by TEE before proceeding
to implantation of an LAA occlusion device.
A careful multiplane 2D TEE analysis (0 to 180)
(39) improves the understanding of complex LAAmorphologies. Slight rotations of the probe are useful
to assess all lobes adequately and to depict additional
lobes. 3D TEE provides a more detailed assessment
and quantitative analysis of the LAA oriﬁce area
compared with 2D TEE (40,41).
MDCT AND CMR. Although TEE is the most widely
used imaging modality for LAA evaluation, MDCT and
CMR are emerging imaging techniques for the pre-
and post-procedural assessment of thrombus forma-
tion, LAA anatomy and function, device assessment,
and the detection of complications post-procedure,
which can provide complementary or additional in-
formation regarding the LAA.
MDCT. MDCT acquires 3D volumetric data sets of the
entire heart, which can be reconstructed by using
numerous planes at different points in time during
the cardiac cycle thus providing accurate assessment
of LAA anatomy. MDCT accurately depicts the
morphology of the LAA ostium, the perimeter of the
LAA oriﬁce, and the angle of the ﬁrst LAA bend.
Measurement of the LAA ostial perimeter is the most
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478reproducible parameter for sizing an LAA occluder
rather than the measurement of its maximum diam-
eter (42,43). MDCT has a 100% sensitivity for
excluding LAA thrombi (44). However, it has a high
rate of false positive tests and poor interobserver
variability (45).
Different LAA morphologies were described
recently by the use of MDCT to categorize the various
LAA shapes: windsock, cactus, cauliﬂower, and
chicken wing (46,47), but the impact of these
different morphologies on procedural outcome after
LAA closure is unknown. Limitations of MDCT
include ionizing radiation, a lower temporal resolu-
tion than TEE, and it cannot be performed during
device deployment.
CMR. Although experience is limited, CMR is an
alternative noninvasive imaging modality in pre-
and post-procedural LAA assessment to accurately
visualize LAA size and function, and to detect
thrombi in patients with AF with effectiveness
comparable with TEE (48–52). LAA devices are typi-
cally made from metals that include nitinol, tita-
nium, titanium alloy, MP35N, 316L stainless steel,
and 304V stainless steel. At 1.5-T, only devices made
from 304V stainless steel displayed weakly ferro-
magnetic qualities. The LAA occluder device has
been tested and ﬁndings indicate that this device
can be safely used at 3.0-T (53). In post-procedural
evaluation contrast-enhanced CMR is feasible to
conﬁrm occluder placement and to detect residual
peridevice leaks (54).
Advantages of CMR include no radiation exposure
or need for iodinated contrast. However, limitations
include the lower spatial resolution, prolonged ex-
amination times, the dependence on the ability to
perform adequate breath holds, and limited ability to
use CMR in patients with implanted pacemakers or
deﬁbrillators or during the device implantation
procedure.
SPECIFIC IMAGING ASPECTS IN
PRE-PROCEDURE PLANNING
DEVICE SIZING FOR ENDOLUMINAL OCCLUSION
DEVICES. Device sizing is of paramount importance
to ensure a stable device position and optimal sealing
of the LAA. Undersizing of the device has the poten-
tial risk of device migration or embolization and may
favor peridevice leakage. Oversizing of the device
should also be avoided because this may cause car-
diac perforation, pericardial effusion, and cardiac
tamponade (11,55,56).
To avoid undersizing, the measurements for device
selection should be performed when the LAA size islargest, namely at the end of ventricular systole and
under normal LA ﬁlling conditions. To accurately
deﬁne ostium diameters, landing zone diameters and
LAA depth measurements should be obtained pre-
procedurally in different echocardiographic views
and intraprocedurally also with the addition of
ﬂuoroscopy.
As shown in Figure 4, when 2D TEE is used (left
panel), the required measurements are obtained by
rotating the TEE transducer array through at least 4
different mid-esophageal planes (typically at w0,
w45, w90, and w135). Because the LAA oriﬁce is
most commonly oval in shape (26) larger oriﬁce di-
ameters can often be found on 120 to 135 planes
rather than at 45 or 90 (57).
Figure 4 (right panel) provides an additional
example of real-time (RT) 3D TEE of the LAA. Several
studies validate that RT 3D TEE more accurately as-
sesses the true LAA oriﬁce size. RT 3D TEE was found
to be closely related to CT measurements (40,41),
whereas 2D TEE tends to underestimate the LAA
oriﬁce area (40,41,58,59).
The choice of an appropriate occlusion device
depends on accurate measurements of the landing
zone diameters. To achieve a secure and stable de-
vice position, the size of the occlusion device is
usually selected to be a few millimeters larger in
diameter than the measurements of the landing zone
(Table 2). The maximum length of the anchoring lobe
has to be measured in addition (in the expected axis
of the device) to ensure that this lobe has enough
space to accommodate the selected device. As illus-
trated in Figure 4 and Table 2, different device
designs require different measurements because
the different endoluminal occluder systems vary
slightly.
The angle between the ostium, the neck, and the
main anchoring lobe should be evaluated because it
can inﬂuence the choice of the puncture site and/or
the curve of the delivery sheath. The number and
origin of additional LAA lobes also needs to be
assessed.
SPECIFIC LAA MORPHOLOGIES. Because some LAA
morphologies are more challenging for device
closure than others, LAA anatomy should be ad-
equately deﬁned before any planned procedure. A
secondary lobe originating close to the ostium
can pose problems, because it may not be covered
after device deployment. Two large lobes of a
similar size separated by a large rim in between
them may cause problems if the remaining prox-
imal portion of the LAA is too short to accommo-
date a device.
FIGURE 4 2D and 3D TEE: Measurements of LAA Dimensions
On the left side 2D TEE measurements of the landing zone diameters and the maximum length of the LAA in the axis of the device are demonstrated in 4 different 2D
imaging planes. LAA occluder device: the landing zone measurement (dotted red line) is performed from the inferior part of the LAA ostium at the level of the circumﬂex
coronary (red dot) to a point 1–2 cm distally to the tip of the rim to the LUPV. The LAA depth (dotted green line) is measured perpendicular to that measurement. LAA
plug devices: the measurement of the landing zone diameter in the anchoring lobe is obtainedw10 mm distally from the ostial plane (dotted yellow line) into the lobe
(dotted white line). The depth of the main lobe (dotted orange line) is measured in the expected axis of the device. Flexible LAA occlusion device: the landing zone
measurement for the ﬂexible LAA occlusion device is performed in a similar way as for the LAA occluder device (dotted red line). The measurement of the depth plays a
minor role as the level of the landing zone marks the distal occluder margin (unlike other devices). The image on the right side gives an example of the 3D TEE
measurement of the landing zone. In this post-processing analysis 45 (upper left panel) and 135 (upper right panel) views are shown. The yellow line demarcates the
landing zone measurement. An enface plane at the level of the landing zone is shown on the lower panel on the left side. Diameters (D1 and D2) and the area (A1) are
measured. An additional 3D enface view (right side, lower panel) shows the LAA oriﬁce in relation to neighboring structures. The white double arrowhead marks the
largest diameter that would be missed by measuring only along the red or green cropping line. Abbreviations as in Figures 1 and 3.
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479A cone-shaped LAA is characterized by progres-
sive reduction in dimensions from its oriﬁce to its
distal tip. A major concern with this morphology is
that compressive forces transmitted by the distal
LAA wall onto the closure device are more pro-
nounced than in the proximal LAA, which can result
in compressive forces that would push the device
out of the LAA toward the oriﬁce and into the LA.
The risk of device migration or embolization is
therefore increased in these patients. Moreover, this
may be further aggravated by the lack of trabecula-
tions in the LAA landing zone region. When an LAA
plug device is used, it has to be taken into consid-
eration that the ostium diameter is considerably
larger than the landing zone diameter in such mor-
phologies. Consequently, the disc may be too small
to seal the ostium adequately in some patients.
Finding a suitable LAA plug size can be challenging
in these patients.A chicken wing LAA morphology, characterized by
an early (<20 mm from the ostium) and severe bend,
is one of the most difﬁcult anatomic variations
for LAA closure. Speciﬁc implantation techniques
may be necessary to achieve LAA occlusion in these
cases (60). We have found that the chicken wing
morphology is generally best evaluated using the long
axis TEE planes (120 to 135).
LAA ASSESSMENT FOR EPICARDIAL LAA LIGATION.
When LAA closure with the LAA ligation device is
planned a spiral CT has to be obtained to clarify LAA
oriﬁce diameters and sizes and LAA orientation and
location. Patients with an LAA width >40 mm or in
whom the LAA is located under a pulmonary artery
(20) are not suitable for suture placement. In patients
with 2 large lobes that are pointing in different
directions, the placement of the suture loop can be
difﬁcult. Patients with prior cardiac surgery or peri-
carditis also are not suitable for the LAA ligation
TABLE 2 Morphologic Device-Speciﬁc Requirements
Endoluminal Extraluminal
LAA Occluder Device
First Generation LAA Plug/
Second Generation LAA Plug Flexible LAA Occlusion Device LAA Ligation Device
Available device sizes 5 device sizes: 21, 24, 27,
30, 33 mm
First generation LAA plug:
8 device sizes: 16, 18, 20, 22,
24, 26, 28, 30 mm (the disc is
4 mm larger for device sizes
up to 22, and 6 mm larger
for device sizes 24–30 mm)
Second generation LAA plug:
8 device sizes: 16, 18, 20,
22 (lobe length 7.5 mm, waist
length 5.5 mm; disc size ¼
lobe size þ 6 mm); 25, 28, 31,
34 mm (lobe length 10 mm,
waist length 8 mm; disc size ¼
lobe size þ 7 mm)
3 device sizes: 22, 27, 32 mm Only 1 device size: a 40-mm
pre-tied suture loop
Ostium diameter* — The ostium diameter has to be
smaller than the disc size
of the selected device
— <40 mm (CT required)
Deﬁnition of where to
measure the landing
zone diameters for
endoluminal devices*
(by TEE)
Measured from the inferior
part of the LAA ostium
at the level of the circumﬂex
coronary artery to a point
1–2 cm distally to the tip
of the rim to the LUPV
Measured at w10 mm distally
from the ostial plane
into the lobe
Measured from the inferior
part of the LAA ostium
at the level of the circumﬂex
coronary artery to a point
1–2 cm distally to the tip
of the rim to the LUPV
—
Required landing
zone diameters
17–31 mm First generation LAA plug:
12.6–28.5 mm
Second generation LAA plug:
11–31 mm
15–29 mm Ostium diameter <40 mm
(CT required)
Sizes up to 70 mm in length
and 20 mm in height
can be treated
Choice of device size 2–4 mm larger than the largest
measured diameter
1.5–3.4 mm larger than the
largest measured diameter
3–8 mm larger than the largest
measured diameter
—
Required depth of main
anchoring lobe
(in the axis of the
device)*
$19 mm for the smallest device
size (21 mm)
The length of the device
progressively increases as
device diameter increases
$10 mm for the ﬁrst generation
LAA Plug and second generation
LAA plugs up to 22 mm.
For larger second generation
LAA plugs: >12mm
#10 mm —
General morphological
exclusion criteria
Presence of a thrombus/cardiac
tumor
Comorbidities other than atrial
ﬁbrillation that require chronic
anticoagulation therapy
Rheumatic valvular disease
Active endocarditis
Additional morphological
exclusion criteria
LVEF <30%; pericardial effusion
>2 mm; high risk PFO; history
of ASD repair or present ASD/PFO
device; signiﬁcant mitral valve
stenosis; complex atheroma
with mobile plaque of the
descending aorta (5)
Presence of an ASD/PFO device;
history of surgical ASD/PFO
repair; history of stroke and
unrepaired PFO; moderate
to severe aortic or mitral valve
stenosis or regurgitation;
pericardial effusion; complex
atheroma with mobile plaque
of the descending aorta and/or
aortic arch (ﬁrst generation
LAA plug registry-long-term
follow-up protocol)
LVEF <30%; mitral valve stenosis
<1.5 cm2; pericardial effusion
>5 mm pre-procedure; presence
of a PFO that demonstrates
a large shunt and/or atrial
septal aneurysm with >10 mm
excursion; (ﬂexible LAA
occlusion device I exclusion
criteria; ongoing trial)
LVEF <30%; a superiorly
orientated LAA with the
LAA apex directed behind
the pulmonary trunk; bilobed
or multilobed LAA in which
lobes are orientated in
different planes exceeding
40 mm; a posteriorly rotated
heart; pericardial adhesions
(patients with prior cardiac
surgery/pericarditis/history or
radiation therapy were also
excluded because of the
high likelihood of pericardial
adhesions) (20)
*All measurements should be performed at the ventricular end-systole and under normal left atrial ﬁlling pressures.
ASD ¼ atrial septal defect; CT ¼ computed tomography; LUPV ¼ left upper pulmonary vein; LVEF ¼ left ventricular ejection fraction; PFO ¼ patent foramen ovale; TEE ¼ transesophageal echocardi-
ography; other abbreviations as in Table 1.
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480device procedure because of the high likelihood of
residual pericardial adhesions, which would interfere
with placement of the LAA ligation device. A TEE pre-
LAA ligation device procedure is important to excludeLAA thrombi, and it provides detailed information on
the number and orientation of lobes. However, it is
not as important for device guidance as TEE is with
the implantable LAA occlusion devices (61).
FIGURE 5 TS Puncture
(A) Viewed from a position in the middle of the interatrial septum (crossing of the white dashed lines) the preferred TS puncture site is located
usually slightly posterior and inferior as demonstrated in A (green area) in a left atrial 3D TEE aspect. (B) Simultaneous 3D TEE (top) and
X-plane imaging (bottom) demonstrates the tent-like indentation of the interatrial septum (white arrowheads). This imaging approach
facilitates the determination of the preferred puncture site (Online Video 1). Factors that can impact the TS puncture, such as the size and
location of the fossa ovalis, the thickness of the interatrial septum, the presence of a persistent foramen ovale, an atrial septum defect, an atrial
septum aneurysm, or an eustachian valve, should be assessed in addition (not shown). RA ¼ right atrium; TS ¼ transseptal; other abbreviations
as in Figures 1 and 2.
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481PERIPROCEDURAL
ECHOCARDIOGRAPHIC ASSESSMENT
During LAA device implantation (10) echocardiogra-
phy is the most important imaging modalityFIGURE 6 Positioning of the Delivery Sheath and Device Deploymen
(A) A 2D and 3D TEE is used simultaneously (3D enface aspects on top,
duction and the position of the delivery sheath into the LAA (left image; w
the occlusion device (a ﬁrst generation LAA plug was implanted in this
(Online Videos 2 and 3). Abbreviations as in Figure 1.to support ﬂuoroscopy and is of paramount impor-
tance to guide transseptal (TS) puncture, to verify
catheter and sheath position in the LAA, to aid de-
vice delivery and positioning, to conﬁrm adequate
LAA sealing, and to detect complications.t
corresponding X-plane views on the bottom) to monitor the intro-
hite arrowheadsmark the delivery sheath) and (B) the positioning of
case; red arrowheads mark the ﬁrst generation LAA plug occluder)
TABLE 3 Criteria of an Appropriate Device Position for Different Endoluminal Devices
Device Criteria of an Appropriate Device Position
LAA occluder device  Position symmetrically in the center of the LAA below
the LAA ostium or at the ostial plane
 8%–20% device compression (some recommend a higher grade
of compression of 15%–30%) (10) (Figure 7)
 Fixations barbs should be in contact with the LAA wall
 The device should not protrude >4–7 mm beyond the LAA ostium
(depending on device size as outlined in the manufacturer’s
instructions for use)
First generation
LAA plug device
 Two-thirds of the lobe should be positioned distal to the
circumﬂex coronary artery
 The distal part of the lobe should have the appearance of a ﬂat
tent, thus indicating some amount of compression on the lobe
 The disc should cover the LAA ostium with a concave appearance
 The ﬂexible waist that connects the disc and the lobe should be
clearly visible
 Fixation anchors should be engaged with the LAA wall
Flexible LAA
occlusion device
 The hub of the occluder on the left atrial side should be located
proximal to the landing zone
 The anchors (best visualized in ﬂuoroscopy) should be placed
w5 mm distal to the landing zone
 A distal contrast injection provides conﬁdence in device position,
stability, and occlusion
 Landing zone ¼ distal occluder margin
Abbreviations as in Tables 1 and 2.
FIGURE 7 Measurement of Device Compression After Implantation
This 3D reconstruction gives an example of the measurement of the dev
measured in different planes: 45, upper panel left side (D1 ¼ 2.33 cm)
measurements, bottom left side (D3 ¼ 2.41 cm; D4 ¼ 2.26 cm). The imag
measured compression is 11% to 16% and therefore in the target range (8
in Figure 1.
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482Multiplanar 2D TEE is most commonly used for
procedural guidance but intracardiac echocardiogra-
phy has also been suggested as a feasible alternative
imaging solution (62,63). Because the interaction of
different moving structures can frequently not be
visualized in one single plane, RT 3D TEE facilitates
the procedure by providing views where targets
(e.g., the LAA), wires, catheters, sheaths, and devices
can be observed in one single view and in relation
to each other. RT 3D TEE provides more accurate
morphological information, facilitates the maneu-
vering and alignment of devices to the target struc-
tures (64), and is recommended for the guidance of
LAA closure procedures (65).
Regardless of the device type chosen to occlude the
LAA, procedural steps with regard to transcatheter
endoluminal LAA closure are similar. The proce-
dure is optimally guided using 2D and 3D TEE
in combination. Before the TS puncture LAA clot
formation has to be excluded once more, the
LAA morphology should be reassessed, and LAAof a 27-mm LAA Occluder Device
ice compression. The device diameter after device implantation is
; 135, upper panel right side (D2 ¼ 2.34 cm); corresponding enface
e on the bottom right side provides a 3D enface view. In this case the
% to 20% ¼ 84% to 89% of the original device size). Abbreviation as
FIGURE 8 Complications
(A) Highly compressed LAA occluder device (white arrows) is placed in 1 deep lobe. Another large lobe is completely uncovered (white asterisk). This situation is shown
using 2D TEE (left) with and without color Doppler and an enface 3D TEE image without (middle) and with (right) color Doppler. (B) Unsuccessful LAA ligation using a
LAA ligation device. A partially closed LAA is seen by using TEE X-plane imaging (left) and color Doppler demonstrating ﬂow coming in and out (middle) and by using a
3D enface view from the left atrial side (right); the black arrows mark the residual leak at the level of the suture ligation. (C–E) Thrombus formation on different devices
(marked with yellow arrows) by using TEE during follow-up (C ¼ LAA occluder device in a 2D TEE plane and a 3D TEE enface view; D ¼ LAA ligation device suture
occlusion in a 3D TEE enface view; E ¼ ﬁrst generation LAA plug in a 3D TEE enface view). Abbreviations as in Figure 1.
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483dimension measurements are repeated and combined
with angiographic measurements to select the most
suitable device type and an appropriately sized de-
vice. As illustrated in Figures 5 and 6 the following
procedural steps have to be monitored: TS puncture
(Online Video 1), positioning of the delivery sheath in
the LAA (Online Video 2), and device deployment
(Online Video 3).
ASSESSMENT OF DEVICE POSITION IMMEDIATELY
POST-PROCEDURE. Complete occlusion of the LAA
and the absence of any alteration of surrounding
structures (left upper pulmonary vein or mitral valve)
should be conﬁrmed immediately after implantationby the use of ﬂuoroscopy and 2D and 3D TEE
(Figure 1). Color-ﬂow Doppler using a low Nyquist
limit is used to assess if there is incomplete LAA oc-
clusion and a persistent communication between the
LAA cavity and the LA. In some patients complete
closure cannot be achieved and a peridevice gap may
occur with any of the currently available devices
(13,17,19,20,66–68).
There is no consensus as to what constitutes a sig-
niﬁcant peridevice leak after LAA device occlusion.
Because there are data for noninferiority in patients
with a residual leak with a jet size #5 mm after
implantation of a LAA occluder device compared
with warfarin therapy in the PROTECT-AF trial
TABLE 4 Speciﬁc Complications During LAA Closure, Their Mechanisms, Incidences, and Prevention/Treatment Options
Complication Mechanism Incidence Treatment/Prevention
Pericardial effusion/tamponade Perforation of the LA or LAA by wires,
catheters, devices
Incorrect transseptal puncture
LAA occluder device: serious pericardial
effusion, up to 5.2% (PROTECT-AF) (5,11)
First generation LAA plug: pericardial
effusion or tamponade in-hospital,
1.24%–3.5% (14)
Flexible LAA occlusion device: 2.7%
up to a 45-day FU (19)
LAA ligation device: signiﬁcant
periprocedural pericardial effusion,
3.7%–10.4% (22,23)
Periprocedural tamponade, 4.5% (23)
Pericardial drainage
Surgery if needed
Device embolization Incorrect sizing, incorrect device
deployment
LAA occluder device: 0.0%–2.7% (5,11)
First generation LAA plug: in-hospital,
0.21%–1.4% (14,16); at FU,
0% (13,15,16)
Flexible LAA occlusion device: 0%
up to 45 days FU (19)
Transcatheter removal (e.g., by the
use of snares)
Surgery if needed
Thrombus formation on the
device or at the closure site
Exposure of foreign material LAA occluder device: 4.2%
(PROTECT-AF) (5,11)
First generation LAA plug: up to 14% (13)
Flexible LAA occlusion device: 0% up to
45 days FU (19)
LAA ligation device: 4.8% (median FU,
122 days) (23)
Anticoagulation therapy
Residual ﬂow into the LAA Incomplete coverage of the LAA LAA occluder device: 8% of patients had a
residual leak >5 mm at 6-month FU (5)
Residual leaks intraprocedural: 27.6%;
29.3% at 45-day FU, and 34.5%
at 1 year (67)
32.0% of implanted patients had at least
some degree of peridevice ﬂow
at 12 months (68)
First generation LAA plug: 16.2% mild
peridevice leakage at 6 months FU;
2.4% ﬂow >3 mm
color jet (16)
Flexible LAA occlusion device: after 45 days
post-implant 3% of patients had a
residual leak >3mm (19)
LAA ligation device: after the procedure,
residual leak <5 mm 8%; >5 mm 0%
(complete closure, 92%) (23); at median
FU of 122 days, residual leak $5 mm 6%,
<5 mm 14%, complete closure 79% (23)
Accurate sizing and assessment of
morphology pre-procedure
Persistent ASD Transseptal sheath placement 11% of patients had a persistent ASD at
6-month and 7% at 12-month FU (71)
The iatrogenic ASDs are usually small
and do not require treatment
Chest pain/pericarditis Pericardial irritation, speciﬁc for the
LAA ligation device procedure
caused by pericardial access
Pericarditis: 14% (3/21) (21) Chest pain usually resolves once the
pigtail catheter is removed from
the pericardium
Pericarditis treatment with
colchicine  NSAIDs
Alteration of the LUPV, the MV
apparatus, or the circumﬂex
coronary artery
Because of their close anatomic
relationship a device placed in the
LAA can theoretically alter the
LUPV, causing pulmonary vein stenosis,
or even alter the MV apparatus or the
circumﬂex coronary artery
To our knowledge no cases describing
one of these potential complications
are reported to date
Pulmonary vein anatomy should be
assessed by 2- and 3-dimensional
TEE and pulmonary vein ﬂow should be
evaluated by the use of color ﬂow and
pulse wave Doppler. A pre- and
post-procedural evaluation should
also include a detailed assessment
of the MV anatomy and grading of
mitral regurgitation severity if present
Repeated ECGs should also be obtained
ECG ¼ electrocardiogram; FU ¼ follow-up; NSAID ¼ nonsteroidal anti-inﬂammatory drug; other abbreviations as in Tables 1 and 2.
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484(the jet-diameter was measured by 2D TEE with color
Doppler in multiple planes; however, absence of a
speciﬁed Nyquist limit represents a limitation) (5),
a peridevice leak #5 mm seems to be acceptable andnot associated with an increased thromboembolic
stroke risk.
Correct device position is of major importance.
If an endoluminally implanted occlusion device
CENTRAL ILLUSTRATION Imaging Approach to LAA Closure: An Overview
LAA Ligation Device
Substantial Variations in LAA Shape
Chicken wing WindsockCactus Cauliflower
TTE        TEE        MDCT       MRI
Measurements critical 
to stable device placement
Large double lobe
ENDOLUMINAL LAA DEVICES 
EPICARDIAL LAA DEVICES 
• Iatrogenic ASD
• Peri-device leakage
• Thrombi 
• Device position
LAA ostium
 
Cone-shaped lobe
Spiral CT
Specific shapes that can
cause difficulties
Peri-Procedural 
Echocardiographic Guidance
Post-Procedural 
Echocardiographic Follow-Up
Lobar region
2DTEE + 3DTEE
2
       Maximum length 
   of anchoring lobe in 
the axis of the device
1
Landing zone
3
LAA Anatomy Assessment 
and Suitability for Closure
Ostium
LUPV
Neck
2DTEE + 3DTEE
• Trans-septal puncture
• Placement of delivery sheath
• Correct device positioning
+ Fluoroscopy
2DTEE + 3DTEE
• Evaluation of contraindications
• LAA dimensions
• Surrounding anatomical 
  landmarks
LAA Occluder Device
First Generation LAA Plug
LAA Occluder Device
First and Second Generation
    LAA Plug
Flexible LAA Occlusion Device 
Mitral v.
Cx
TEE
• Evaluation of contraindications
• LAA ostium and anatomical
   assessments
• Magnetic wire placement
  within LAA during procedure
Top left panel shows a cross section of the left atrium and the orientation of the LAA, left circumﬂex coronary artery, mitral valve as well as the
left upper pulmonary vein. Top right panel depicts the various LAA morphologies and shapes. Middle panel demonstrates the critical locations
where measurements need to be made for optimal sizing of the LAA occlusion device. Bottom left panel illustrates the optimal placement of
LAA occluder device and ﬁrst generation LAA plug for LAA occlusion. ASD ¼ atrial septal defect; CT ¼ computed tomography; Cx ¼ circumﬂex
coronary artery; LAA ¼ left atrial appendage; LUPV ¼ left upper pulmonary vein; MDCT ¼ multidetector computed tomography;
MRI ¼ magnetic resonance imaging; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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486is placed too deep into the LAA, more proximal orig-
inating lobes may be uncovered. For cases in which
the device is implanted too proximal in the LAA the
occluder may not be adequately compressed by the
LAA walls and thus be unstable and it can embolize.
Table 3 summarizes criteria for appropriate posi-
tioning for different endoluminal devices. A certain
amount of device compression is needed with every
device. Figure 7 gives an example of the evaluation of
device compression after implantation of an LAA
occluder device.
After a device is inserted, but before its release
from the catheter, gentle traction on the catheter is
applied to the device (“tug” test) to demonstrate that
the device positioning is stable. The device and the
surrounding tissues should move in unison during
the tug test.
DETECTION OF COMPLICATIONS. Complications
may occur at any time during the intervention and
during patient follow-up. Figure 8 demonstrates
echocardiographic examples of acute and delayed
complications of LAA exclusion. The immediate
detection of acute complications by echocardiogra-
phy is of paramount importance to minimize or avoid
adverse clinical consequences. Table 4 provides an
overview of potential complications, their mecha-
nism and incidence, and prevention and treatment
strategies.
POST-PROCEDURAL
ECHOCARDIOGRAPHIC FOLLOW-UP
TTE is recommended after the intervention before the
patient is discharged from the hospital to conﬁrm that
no relevant device migration occurred and to
exclude the development of a pericardial effusion.
TEE is often used for standard echocardiographic
follow-up at 1, 3, or 6 and 12 months, then annually
(when there is no evidence of device migration or
complications after 1 year further surveillance can
be done annually by using TTE; in case there is an
abnormality that needs clariﬁcation, TEE should be
performed in addition) to reassess the implanted
device for a stable position, migration or emboliza-
tion, erosion, thrombus formation, and peridevice
gaps. Echocardiography is also used to monitor for
any interference with neighboring structures, such
as the mitral valve, left upper pulmonary vein, and
the circumﬂex coronary artery; but to our knowledge
no such cases have been reported to date. The for-
mation of a thrombus or ﬁbrosis within the LAA cavity
distal to the occlusion device is a normal ﬁnding
but careful attention is warranted to evaluate newlydeveloped thrombotic clots either attached to the
device or within the LA because this would be an
indication for anticoagulation therapy.
Complete closure of the LAA represents one of
the major determinants of a successful procedure.
Nevertheless, the presence of a peridevice leak is a
common ﬁnding and there are no data at present that
demonstrate that it is associated with an increased
risk of stroke (67–69).
Notably it has been shown that intraprocedural
leaks can become larger over time and persist for
more than 1 year, and new peridevice leakages can
also occur during follow-up (66). Consequently, it
is important for patients to have serial follow-up
echocardiograms. Despite there being no deﬁnitive
data, it is currently recommended (according to
the PROTECT-AF data) that anticoagulation therapy
should be continued if there is a persistent peridevice
gap >5 mm (5). In some patients with a relevant leak
resulting from an uncovered lobe the implantation
of a second device is an option to complete LAA
closure (70).
During each follow-up atrial septal defect second-
ary to the TS puncture should be reassessed by the
use of TEE (2D or 3D) with and without color Doppler.
Saline contrast injections along with a Valsalva
maneuver are useful to identify the presence of a
right-to-left shunt. These iatrogenic atrial septal
defects have a high spontaneous closure rate over
time. In one study, only 11% of patients had a
persistent atrial septal defect at 6 months and 7% at
12 months after the procedure. Moreover, to date,
residual atrial septal defects have not been associated
with an increased rate of stroke or systemic emboli-
zation during long-term follow-up (71).
CONCLUSIONS
LAA device closure is a relatively new, but evolving
treatment strategy to prevent embolic events in
patients suffering with nonvalvular AF. Echocardiog-
raphy, using both 2D and 3D TEE, currently repre-
sents the most important imaging tool to assess the
suitability of the LAA anatomy for the procedure, for
selecting the optimal device types and sizes, for guid-
ing the LAA closure procedure in conjunction with
ﬂuoroscopy, and for follow-up imaging after device
implantation.
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